A detailed history of Omers Administration Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Omers Administration Corp holds 114,302 shares of BMY stock, worth $6.6 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
114,302
Previous 79,402 43.95%
Holding current value
$6.6 Million
Previous $3.3 Million 79.41%
% of portfolio
0.06%
Previous 0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$39.66 - $51.75 $1.38 Million - $1.81 Million
34,900 Added 43.95%
114,302 $5.92 Million
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $3.2 Million - $4.21 Million
79,402 New
79,402 $3.3 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $9.23 Million - $13.4 Million
-198,900 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $1.63 Million - $2.12 Million
-33,100 Reduced 14.27%
198,900 $12.8 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $2.09 Million - $2.48 Million
48,900 Added 26.71%
232,000 $11.8 Million
Q2 2019

Aug 08, 2019

BUY
$44.62 - $49.34 $6.76 Million - $7.47 Million
151,400 Added 477.6%
183,100 $8.42 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $1.43 Million - $1.71 Million
31,700 New
31,700 $1.57 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $7.27 Million - $9.43 Million
-149,100 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $822,331 - $927,525
-14,900 Reduced 9.09%
149,100 $9.26 Million
Q2 2018

Aug 09, 2018

BUY
$50.53 - $62.98 $3.62 Million - $4.52 Million
71,700 Added 77.68%
164,000 $9.08 Million
Q1 2018

May 11, 2018

BUY
$59.92 - $68.98 $5.53 Million - $6.37 Million
92,300 New
92,300 $5.84 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Omers Administration Corp Portfolio

Follow Omers Administration Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Omers Administration Corp, based on Form 13F filings with the SEC.

News

Stay updated on Omers Administration Corp with notifications on news.